Cite
HARVARD Citation
Ou, S. et al. (n.d.). I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib. Lung cancer. 88 (2), pp. 231-234. [Online].